CompletedPhase 3Phase 4ACTRN12611000241932

CoQ10 treatment in inadequately treated hypertensive patients with the metabolic syndrome.

A double-blind, randomised, placebo controlled, 12-week cross-over study to assess the effect of Coenzyme Q10 treatment on 24hr mean ambulatory systolic and diastolic blood pressure in inadequately treated hypertensive patients with the metabolic syndrome.

Sponsor

Canterbury Health Laboratories

Enrollment

30 participants

Start Date

Dec 1, 2008

Study Type

Interventional

Conditions

Hypertension The Metabolic Syndrome

Summary

CoQ10 has been reported to lower blood pressure. We are giving supplemental CoQ10 to 30 participants with the metabolic syndrome and uncontrolled high blood pressure, despite medication, to determine whether CoQ10 can further lower their blood pressure, and reduce their risk of serious disease.

Eligibility

Sex: Both males and femalesMin Age: 25 YearssMax Age: 75 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests whether CoQ10 supplements can help lower blood pressure in people who already take blood pressure medication but still have readings that are too high, and who also have metabolic syndrome. Participants must be aged 25 to 75 and on stable blood pressure medication for at least one month.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Coenzyme Q10 (100mg twice daily) or placebo (twice daily) for 12 weeks via oral capsule, followed by a 4-week washout period, then 12 weeks of the alternate 'treatment'.